Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Drug Delivery in Paediatric Brain Tumours /
Intrathecal cytarabine for paediatric brain tumours

1st - 2nd Feb 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 08.02.16
Views: 1944

Dr Irene Slavc - Medical University of Vienna, Vienna, Austria

Dr Slavc talks to ecancertv at Children with Cancer UK’s workshop on Drug Delivery in Paediatric Brain Tumours in London, UK.

In the interview she discusses the use of intrathecal cytarabine to treat children with brain tumours such as medulloblastoma.

Intrathecal cytarabine has been used for decades to treat patients with acute myeloid leukaemia who have occult or overt central nervous system (CNS) involvement.

A liposomal formulation was developed in the 1980s with the aim of providing sustained release and which makes it particularly suitable for use as an intrathecal therapy.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation